Latanoprost / Timolol Crescent Pharma (Timolol Maleate, Latanoprost)

• Latanoprost/Timolol is used in the management of ocular conditions that require reduction of intra‑ocular pressure.
• Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression.
• Ocular hypertension: reduces eye pressure to prevent conversion to glaucoma.
• Secondary glaucoma: provides adjunctive pressure control when monotherapy is insufficient.

• Latanoprost, a prostaglandin F2α analog, increases uveoscleral outflow of aqueous humor by remodeling extracellular matrix in the ciliary body. Timolol maleate, a non‑selective beta‑adrenergic antagonist, reduces aqueous humor production by blocking β1 and β2 receptors in the ciliary epithelium, together resulting in a net decrease of intra‑ocular pressure.

Common Side Effects

• Eye irritation or burning sensation.
• Blurred vision shortly after instillation.
• Conjunctival hyperemia (redness).
• Increased eyelash length or density.
• Darkening of the iris color.
• Mild headache.

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, swelling).
• Sudden loss of vision or acute ocular pain.
• Systemic bradycardia or hypotension.
• Bronchospasm in susceptible individuals.
• Persistent corneal ulceration.
• Significant worsening of asthma or COPD.

Before using Latanoprost/Timolol, consider the following precautions:

• Assess cardiovascular status: avoid in patients with severe bradycardia, heart block, or uncontrolled heart failure.
• Screen for respiratory disease: use with caution in asthma or COPD due to beta‑blocker effects.
• Monitor for ocular allergy: discontinue if severe conjunctival reaction occurs.
• Avoid concurrent use with other beta‑blocker eye drops to prevent additive systemic absorption.
• Pregnancy and lactation: prescribe only if clearly needed after risk‑benefit assessment.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines as follows:

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: may cause additive bradycardia or hypotension.
• Sympathomimetic ophthalmic agents (e.g., phenylephrine): may reduce the ocular hypotensive effect.
• Other prostaglandin analog eye drops: increased risk of ocular irritation and hyperemia.

Moderate Interactions (Monitor Closely)

• Systemic antihypertensives: monitor blood pressure for additive lowering.
• Inhaled beta‑agonists (e.g., albuterol): watch for reduced bronchodilator response.
• Topical anesthetics: may increase corneal toxicity when used together.